Study #2025-0867
A global multicenter, double-blind, randomized, registrational phase 3 study of Lisaftoclax (APG-2575) in combination with Azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS) (GLORA-4)
MD Anderson Study Status
Enrolling
Treatment Agent
Lisaftoclax (APG-2575), Azacitidine Injection
Description
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Higher-risk Myelodysplastic Syndrome
Study phase:
Phase III
Physician name:
Guillermo Garcia-Manero
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.